At the news
? BEARISHIMPACT 6/10 6-K filed Jul 15, 2026 at 09:45 ET
Dr. Reddy's disclosed a manufacturing impurity issue in the scale-up of its semaglutide injection API, causing a halt in commercial supply for approximately three months. The company now expects to supply only 6-7 million pens in FY27 (down from prior guidance of ~12 million), with no patient safety impact or recall. This is a material negative for near-term revenue from its key GLP-1 product.
- Impurity (degradation) detected in finished drug product from a scale-up validation batch of semaglutide injection API.
- Commercial supply halted until process is fixed and re-validated; expected resumption late October/early November 2026.
- FY27 semaglutide pen guidance revised to 6-7 million pens (from prior ~12 million), with supply concentrated in Q3-Q4.
- No patient safety impact, no recall of previously supplied product, and no impact on oral semaglutide or existing regulatory filings.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access